Mary Sifain, DO
Nephrology · Boca Raton, FLNPI 1013474188
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,196, more than ten times the $24 reported in 2021.
Across 92 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- OPKO Pharmaceuticals, LLC$260
- Otsuka America Pharmaceutical, Inc.$245
- Novartis$231
- AstraZeneca$174
- Travere Therapeutics, Inc.$171
- Aurinia Pharma U.S., Inc.$132
- plus $837 from 16 others
What the payments were for
- Food & beverage$2,050100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| OPKO Pharmaceuticals, LLC | 18 | $260 |
| Otsuka America Pharmaceutical, Inc. | 9 | $245 |
| Novartis | 10 | $231 |
| AstraZeneca(2 entities) | 6 | $174 |
| Travere Therapeutics, Inc. | 9 | $171 |
| Aurinia Pharma U.S., Inc. | 5 | $132 |
| Novo Nordisk | 4 | $106 |
| Bayer | 5 | $98 |
| Vifor Pharma, Inc. | 3 | $87 |
| Mallinckrodt Hospital Products Inc. | 3 | $79 |
| ANI Pharmaceuticals, Inc. | 3 | $66 |
| Lilly USA, LLC | 3 | $64 |
| Ardelyx, Inc. | 3 | $61 |
| Calliditas Therapeutics US Inc. | 2 | $54 |
| Boehringer Ingelheim | 2 | $49 |
| GSK | 1 | $29 |
| Baxter Healthcare | 1 | $28 |
| Amgen | 1 | $25 |
| Edwards Lifesciences | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Invivyd Inc | 1 | $22 |
How this compares
$2,050 in reported general payments places this provider in the 60th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Boca Raton
- Marc RichardsBoca Raton$61K
- Jared JaffeBoca Raton$19K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.